Nanopore ReCappable sequencing maps SARS-CoV-2 5′ capping sites and provides new insights into the structure of sgRNAs. Issue 6 (4th March 2022)

• Record Type: Journal Article
• Authors: Ugolini, Camilla; Mulroney, Logan; Leger, Adrien; Castelli, Matteo; Criscuolo, Elena; Williamson, Maia Kavanagh; Davidson, Andrew D; Almuqrin, Abdulaziz; Giambruno, Roberto; Jain, Miten; Frigè, Gianmaria; Olsen, Hugh; Tzertzinis, George; Schildkraut, Ira; Wulf, Madalee G; Corrêa, Ivan R; Ettwiller, Laurence; Clementi, Nicola; Clementi, Massimo; Mancini, Nicasio; Birney, Ewan; Akeson, Mark; Nicassio, Francesco; Matthews, David A; Leonardi, Tommaso
• Is Part Of: Nucleic acids research. Volume 50:Issue 6(2022)
• Page Start: 3475
• Page End: 3489
• Publication Date: 2022-03-04
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkac144
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: The SARS-CoV-2 virus has a complex transcriptome characterised by multiple, nested subgenomic RNAsused to express structural and accessory proteins. Long-read sequencing technologies such as nanopore direct RNA sequencing can recover full-length transcripts, greatly simplifying the assembly of structurally complex RNAs. However, these techniques do not detect the 5′ cap, thus preventing reliable identification and quantification of full-length, coding transcript models. Here we used Nanopore ReCappable Sequencing (NRCeq), a new technique that can identify capped full-length RNAs, to assemble a complete annotation of SARS-CoV-2 sgRNAs and annotate the location of capping sites across the viral genome. We obtained robust estimates of sgRNA expression across cell lines and viral isolates and identified novel canonical and non-canonical sgRNAs, including one that uses a previously un-annotated leader-to-body junction site. The data generated in this work constitute a useful resource for the scientific community and provide important insights into the mechanisms that regulate the transcription of SARS-CoV-2 sgRNAs.